Evidence map›Paper›PMID 33594613›Full record

ArticleMedical oncology (Northwood, London, England)2021

ERVs-TLR3-IRF axis is linked to myelodysplastic syndrome pathogenesis.

Roberta Taiane Germano de Oliveira, João Victor Alves Cordeiro, Bruna Ferreira Vitoriano, Mayara Magna de Lima Melo, Letícia Rodrigues Sampaio, Daniela de Paula Borges, Silvia Maria Meira Magalhães, Ronald Feitosa Pinheiro

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Roberta Taiane Germano de OliveiraCancer Cytogenomic Laboratory, Federal University of Ceará, Fortaleza, Ceará, Brazil.
João Victor Alves CordeiroCancer Cytogenomic Laboratory, Federal University of Ceará, Fortaleza, Ceará, Brazil.
Bruna Ferreira VitorianoCancer Cytogenomic Laboratory, Federal University of Ceará, Fortaleza, Ceará, Brazil.
Mayara Magna de Lima MeloCancer Cytogenomic Laboratory, Federal University of Ceará, Fortaleza, Ceará, Brazil.
Letícia Rodrigues SampaioCancer Cytogenomic Laboratory, Federal University of Ceará, Fortaleza, Ceará, Brazil.
Daniela de Paula BorgesCancer Cytogenomic Laboratory, Federal University of Ceará, Fortaleza, Ceará, Brazil.
Silvia Maria Meira MagalhãesCancer Cytogenomic Laboratory, Federal University of Ceará, Fortaleza, Ceará, Brazil.
Ronald Feitosa PinheiroCancer Cytogenomic Laboratory, Federal University of Ceará, Fortaleza, Ceará, Brazil. pinheirorfeitosa@gmail.com.ORCID http://orcid.org/0000-0002-7965-1409
Universidade Federal do Ceará · BR

Funding

CNPq 420501/2018-5
6 · The paper itself

Abstract

Toll-like receptors are mutated or overexpressed in up to 50% of patients with myelodysplastic syndrome (MDS). Endogenous retroviruses (ERV) trigger TLR3 leading to interferon regulatory genes (IRFs) activation. We evaluated if the ERVs-TLR3-IRF axis activation would be linked to MDS pathogenesis and we also conducted a detailed cancer analysis of the ERVs, TLR3 and IRFs gene expression in 30 cancer types using GEPIA database. Seventy-nine bone marrow samples from patients with MDS were evaluated for cytogenetics and quantitative real‑time PCR of TLR3, ERVK6, ERVW-1, ERV3-1, IRF3 and IRF7. Patients with dyserythropoiesis showed higher TLR3 (p = 0.035), ERVK6 (p = 0.001), ERVW1 (p = 0.045) and ERV3-1 (p = 0.016) expression than patients without dyserythropoiesis. Upregulation of Interferon Regulatory Factors, IRF3 and IRF7, was associated with poor prognostic markers in MDS such as > 10% of blasts (p = 0.003-IRF3; p = 0.009-IRF7), low platelets count (< 50.000/mm

Indexed as

Gene Expression Regulation, NeoplasticAdultAgedAged, 80 and overBiomarkers, TumorEndogenous RetrovirusesFemaleHumansInterferon Regulatory Factor-3Interferon Regulatory Factor-7MaleMiddle AgedMyelodysplastic SyndromesPrognosisToll-Like Receptor 3Young AdultBiomarkers, TumorInterferon Regulatory Factor-3Interferon Regulatory Factor-7IRF3 protein, humanIRF7 protein, humanTLR3 protein, humanToll-Like Receptor 3Endogenous retrovirusesInterferon regulatory genesMyelodysplastic syndromeToll-like receptors

Identifiers

PMID33594613
OpenAlexW3129201345

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.